Statistical Leadership: Its Importance, Imperatives, and Impacts

摘要

The 2018 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop held in September featured a session titled "Statistical Leadership: Its Importance, Imperatives, and Impacts." The session-organized by Adeniyi Adewale and Allison Florance of Novartis and chaired by Steve Lane of BMS-consisted of two presentations representing industry and regulatory perspectives on statistical leadership by Gary Sullivan from Espirer Consulting and John Scott of the FDA, respectively. After the presentations, panelists Eric Gibson of Novartis, Gary Rosner of The Johns Hopkins University, and Janet Wittes of Statistics Collaborative corroborated the presentations with their own experiences. Here are summaries of the presentations and an excerpt of the discussion that followed.